- Moderna Inc (NASDAQ:MRNA) has exercised its option to license Autolus Therapeutics plc’s (NASDAQ:AUTL) proprietary binders against an undisclosed immuno-oncology target for the development and commercialization of mRNA therapeutics.
- This follows an original agreement with Moderna announced in August 2021, granting Moderna an exclusive option to license Autolus’ proprietary binders for up to four immuno-oncology targets for incorporation in certain mRNA therapeutics.
- Related: Moderna Shares Are Surging After Merck Exercised Personalized Cancer Vaccine Pact.
- On exercise of the option, Autolus has received an option exercise payment and is eligible to receive development and commercial milestone payments for each product successfully commercialized.
- In addition, Autolus would receive royalties on net sales of all products commercialized under the agreement.
- Price Action: AUTL shares are up 8.89% at $3.24 on the last check Wednesday.
Genpact And Walmart Extend Partnership In North America
Contract extension builds on collaborative relationship to layer digital technology into finance operations
NEW YORK, June 27, 2023 /PRNewswire/ -- Genpact (NYSE:G), a global professional services
